News JPM: AbbVie pays $650m upfront for RemeGen cancer drug AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.
News Genmab ends lung cancer drug development Genmab has decided to stop development of a drug for cancer, acasunlimab for non-small cell lung cancer, following a review of its pipeline.
Oncology ESMO25: Immuno-therapies and translational research in oncol... Dr Inge Marie Svane – Professor in Clinical cancer immune therapy and director of the translational research centre, CCIT, on IO Biotech's ESMO25 data
News Regulatory T-cell scientist trio wins Nobel Prize The Nobel Prize in Physiology or Medicine goes to three scientists for their work on regulatory T-cells, spawning hundreds of trials of new therapies.
News UK's Trogenix raises £70m for cancer immunotherapy platform Edinburgh-based Trogenix has raised £70m to fund clinical trials of its triple-acting immunotherapies for brain and colorectal cancers.
News Umoja's in vivo cell therapy fast-tracked by FDA A pioneer of in vivo cell therapy, Umoja has cleared another regulatory milestone by getting fast-track status for its lead blood cancer programme.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.